Structured evidence table for Magnesium Endothelial Function Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Magnesium Endothelial Function Randomized Trial | Importantly, these biological changes manifest most meaningfully through declines in functional capacity, including reduced muscle strength, impaired metabolic regulation, diminished cognitive performance, and increased disease risk. | 4 | Kurtz Jennifer A. (2026) | Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits |
| Magnesium Endothelial Function Randomized Trial | This article aims to synthesize evidence from human studies evaluating dietary supplements that directly or indirectly modulate the recognized hallmarks of aging, such as mitochondrial dysfunction, oxidative stress, inflammation, and proteostasis. | 4 | Kurtz Jennifer A. (2026) | Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits |
| Magnesium Endothelial Function Randomized Trial | Rather than providing an exhaustive account of all supplements ever studied, this review focuses on representative compounds with the strongest or most emerging human evidence. | 4 | Kurtz Jennifer A. (2026) | Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits |
| Magnesium Endothelial Function Randomized Trial | Aging is a complex, multifaceted process marked by a gradual decline in physiological. | 4 | Kurtz Jennifer A. (2026) | Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits |
| Magnesium Endothelial Function Randomized Trial | Although Mg is frequently discussed as an analgesic supplement, emerging evidence suggests that it acts as a neurovascular-metabolic modulator. | 4 | Yoon Y (2026) | Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain. |
| Magnesium Endothelial Function Randomized Trial | Low magnesium status has been associated with endothelial dysfunction, atherosclerotic burden, impaired microcirculatory function, and overlapping ischemic and neuropathic pain phenotypes, although direct causal clinical evidence remains limited. | 4 | Yoon Y (2026) | Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain. |
| Magnesium Endothelial Function Randomized Trial | The evidence is strongest for mechanistic vascular and neuropathic pathways, whereas direct clinical evidence for magnesium supplementation in PAD-related ischemic limb pain remains limited. | 4 | Yoon Y (2026) | Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain. |
| Magnesium Endothelial Function Randomized Trial | Magnesium (Mg) is an essential divalent cation involved in more than 600 enzymatic reactions and plays a fundamental role in vascular, metabolic, and neural homeostasis. | 4 | Yoon Y (2026) | Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain. |
Source documents